Frequency of TERT promoter mutations in primary tumors of the liver

Virchows Archiv

Volumn 465, Issue 6, 2014, Pages 673-677

  Quaas, Alexander ^a   Oldopp, Theresa ^a   Tharun, Lars ^a   Klingenfeld, Catina ^a   Krech, Till ^a   Sauter, Guido ^a   Grob, Tobias J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Hepatocellular adenoma; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; TERT promoter mutation

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CHILD; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LIVER ADENOMA; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION SITE; SOMATIC MUTATION; ADENOMA; BILE DUCT TUMOR; GENETICS; INTRAHEPATIC BILE DUCT; LIVER TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; YOUNG ADULT;

ADENOMA; ADOLESCENT; ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHILD; CHOLANGIOCARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; TELOMERASE; YOUNG ADULT;

EID: 84914125601     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1658-7     Document Type: Article

References (19)

1. Mocellin S, Pooley KA, Nitti D (2013) Telomerase and the search for the end of cancer. Trends Mol Med 19(2):125–133. doi:10.1016/j.molmed.2012.11.006
2. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961. doi:10.1126/science.1230062
3. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959. doi:10.1126/science.1229259
4. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110(15):6021–6026. doi:10.1073/pnas.1303607110
5. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. doi:10.1038/ncomms3218
6. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R (2013) TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 110(43):17426–17431. doi:10.1073/pnas.1310522110
7. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185. doi:10.1038/ncomms3185
8. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0
9. Liu S, Chan KW, Wang B, Qiao L (2009) Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 104(10):2617–2624. doi:10.1038/ajg.2009.440, quiz 2625
10. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M (2008) Malignant transformation of hepatic adenomas. Mod Pathol 21(4):491–497. doi:10.1038/modpathol.2008.8
11. Nault JC, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144(5):888–902. doi:10.1053/j.gastro.2013.02.032
12. Patel T (2006) Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3(1):33–42. doi:10.1038/ncpgasthep0389
13. Nzeako UC, Goodman ZD, Ishak KG (1995) Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 76(4):579–588
14. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. World Health Organizatin Classification of Tumours, 4 edn.
15. Chan SH, Opitz L, Higgins L, O’Loane D, Xu SY (2010) Cofactor requirement of HpyAV restriction endonuclease. PLoS ONE 5(2):e9071. doi:10.1371/journal.pone.0009071
16. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65(2):360–366. doi:10.1016/j.eururo.2013.08.052
17. Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65(2):367–369. doi:10.1016/j.eururo.2013.08.057
18. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73(24):7162–7167. doi:10.1158/0008-5472.CAN-13-2498
19. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F, Wang D, Cai Z (2014) Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol 65(2):274–277. doi:10.1016/j.eururo.2013.10.038